"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label CRSP. Show all posts
Showing posts with label CRSP. Show all posts

Tuesday, November 17, 2026

An Alternative to an Uncertain AI Trade - medicine and, in particular, Genetics

 


Investment Note: Gene editing in focus

Why I like BEAM, CRSP and NTLA 

The Next Medical Revolution — and an Alternative to an Uncertain AI Trade

November 16, 2026 | Investment horizon: 2027–2028

A potentially historic turning point in medicine

Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.

While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.

This is no longer simply theoretical science.

Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.

Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade.  I am now considering entering positions again.

1. Beam Therapeutics (BEAM): My first choice

Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.

This potentially provides a more precise way of addressing the genetic causes of disease.

On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.

Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.

Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.

Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.

I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.

2. CRISPR Therapeutics (CRSP): The commercial validation

CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.

Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.

CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.

The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.

Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.

A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.

3. Intellia Therapeutics (NTLA): The potentially historic catalyst

Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.

Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.

In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.

The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.

If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.

That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.

Intellia also has a strategic relationship with Regeneron Pharmaceuticals.

Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.

However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.

4. Why Big Pharma could become interested

Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.

Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.

Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.

I see three potential reasons for acquisition interest:

  • Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.

  • Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.

  • Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.

Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.

Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.

I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.

Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.

5. Why consider these investments now, amid the Nvidia controversy?

The timing of this opportunity is particularly interesting.

Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.

The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.

More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.

Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.

I do not believe this necessarily means the AI revolution is ending.

However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.

Genetic medicine offers a compelling alternative.

Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.

Their catalysts are different.

This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.

Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.

6. My proposed investment approach

I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.

Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:

CompanyAllocationInvestment role
BEAM45%Primary technology and growth position
CRSP40%Commercial validation and broader pipeline
NTLA15%Higher-risk regulatory and takeover optionality

I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.

There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.

7. My investment conclusion

I believe we may be approaching an important inflection point in genetic medicine.

For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.

The medical implications are extraordinary, and the commercial implications could be substantial.

At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.

My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:

  1. The transition of gene editing from experimental science toward commercial medicine.

  2. The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.

  3. The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.

I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.

The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.

The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.

The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.

Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.

Research supporting the note

The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.

Beam Therapeutics+2

For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition

Ed Note:

I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!

Thursday, August 28, 2025

BEAM Therapeutics - A simplified investor report!

 


Beam Therapeutics (NASDAQ: BEAM)

Simplified Investor Report – August 2025


1. What Beam Does

Beam is a gene-editing company that uses a next-gen technology called base editing.
Unlike traditional CRISPR, which “cuts” DNA, base editing changes single letters of DNA directly. This makes edits potentially safer and more precise.

Beam’s approach is being tested in blood diseases, liver diseases, and cancer cell therapies.


2. Current Pipeline (Key Drugs in Development)

  • BEAM-101 (Sickle Cell Disease / Beta Thalassemia)

    • Ex vivo (patient’s stem cells edited outside body).

    • Goal: Increase fetal hemoglobin to prevent sickling.

    • FDA gave RMAT designation in Aug 2025—can speed approval.

    • Competes with CRISPR Tx’s already-approved Casgevy.

  • BEAM-302 (Alpha-1 Antitrypsin Deficiency, AATD – In vivo)

    • Liver-targeted using LNPs (same delivery as mRNA vaccines).

    • First clinical proof: restored missing protein in patients. Big de-risking milestone.

  • BEAM-301 (GSD-Ia, rare metabolic disease – In vivo)

    • First patients dosed in 2025. Very rare disease but clear genetic target.

  • BEAM-201 (Allogeneic CAR-T for T-cell leukemia)

    • First multiplex-edited CAR-T (4 edits in one cell).

    • Potential for “off-the-shelf” cancer treatment.

Why this matters: 

Beam is not a “one trick pony”—it has 4 very different programs in the clinic (blood, liver, metabolic, cancer). This spreads risk.


3. How Beam Compares to Other Gene Editors

CompanyTechnologyStatusNotes
Beam (BEAM)Base editing4 clinical programs (in-vivo + ex-vivo + CAR-T)Broadest pipeline; proof of editing in humans (AATD).
CRISPR Tx (CRSP)CRISPR/Cas9First FDA-approved therapy (Casgevy)First mover, but rollout is slow & complex.
Intellia (NTLA)CRISPR/Cas9ATTR program in Phase 3Closest to an in-vivo commercial therapy.
Editas (EDIT)CRISPRHb disorders in Phase 2Smaller player; similar to CRSP but later.
Verve (VERV)Base editingLDL cholesterol lowering in Phase 1Early but strong human data.
Prime Medicine (PRME)Prime editingFirst patients dosedVery early stage, but big potential.

Takeaway: Beam sits between CRSP’s proven approval and Intellia’s Phase 3 lead, but has more breadth than most others. Verve and Prime validate the editing class, but are earlier.

Ed Note:  We like all six and are currently invested in two of these names!


4. Why Analysts & Institutions Are Bullish

  • Analysts: 12–13 Buys, targets $40–80 (2–4x upside from ~$17 today).

  • Catalysts: RMAT for BEAM-101, clinical proof in BEAM-302, first patients dosed in BEAM-301.

  • Big investors buying: ARK Invest, Vanguard, Swiss National Bank, others.

  • Upside potential: If one of Beam’s in-vivo therapies works, it could transform rare disease treatment—making Beam a takeover target for big pharma.


5. Risks to Consider

  • Still pre-revenue—cash burn is high.

  • Competes against already-approved products (Casgevy in SCD).

  • In-vivo gene editing is very new—long-term safety still being proven.

  • Stock is volatile and heavily tied to trial readouts.


6. Bottom Line for Retail Investors

Beam is a high-risk, high-reward biotech.

  • It has a broad and diverse pipeline (blood, liver, rare metabolic disease, CAR-T).

  • Analysts see 2–4x upside in the next 12–24 months.

  • Beam is not yet proven commercially, but recent trial wins (esp. BEAM-302) show that base editing works in humans.

  • For investors who can tolerate volatility, Beam is one of the most exciting gene-editing plays—but it should be sized carefully in a portfolio.

Ed Note:  We are long BEAM NTLA CRSP EDIT



Monday, May 26, 2025

As genetic medicine technology continues to advance, we own both BEAM and CRSPR for their cutting edge tech!



Business & Investment Report: 

Combined Investment Strategy in Beam Therapeutics (BEAM) and CRISPR Therapeutics (CRSP)


Executive Summary: Beam Therapeutics and CRISPR Therapeutics are at the forefront of gene editing, offering complementary but distinct technologies with transformative medical potential. Investing in both provides a blended exposure to early-stage innovation and commercialized gene therapies. This report outlines the rationale for a combined investment, technological differences, clinical advances, and projected value for the healthcare sector.


1. Company Overview

Beam Therapeutics (NASDAQ: BEAM)

  • Specializes in base editing, a refined form of CRISPR technology that enables precise, single-base DNA changes without causing double-stranded breaks.

  • Early-stage pipeline with flagship candidate BEAM-302, targeting Alpha-1 Antitrypsin Deficiency (AATD).

  • Holds ~$1B in cash with clinical runway through 2027.

CRISPR Therapeutics (NASDAQ: CRSP)

  • A leader in CRISPR/Cas9-based gene editing, focused on gene knockouts and repair via double-stranded breaks.

  • First to market with an FDA- and EMA-approved gene therapy: CASGEVY (exa-cel) for sickle cell disease and beta-thalassemia.

  • Backed by strong partnerships, particularly with Vertex Pharmaceuticals.


2. Technological Comparison:       Base Editing vs. CRISPR/Cas9


FeatureBeam Therapeutics (Base Editing)CRISPR Therapeutics (CRISPR/Cas9)
MechanismPrecise base substitutions (no DNA breaks)Gene knockout/repair (via DNA cutting)
SafetyLower risk of off-target effectsHigher off-target risk; immune response possible
PrecisionSingle-base changesLarger edits or gene disruptions
Use CasesPoint mutation diseases (e.g., AATD, sickle cell)Gene knockout therapies (e.g., sickle cell, cancer)

3. Clinical Pipeline & Progress

Beam Therapeutics

  • BEAM-302 (AATD):

    • FDA-cleared IND (March 2025)

    • RMAT designation (May 2025) for potential curative single-dose therapy

    • Early Phase 1/2 data shows dose-dependent correction of AAT protein levels

  • BEAM-101 (sickle cell): preclinical

  • Expanding pipeline in liver, hematologic, and ocular genetic diseases

CRISPR Therapeutics

  • CASGEVY (Exa-cel):

    • FDA + EMA approved for sickle cell and beta-thalassemia

    • Commercial launch ongoing with Vertex (60/40 profit split)

  • CTX130 (CAR-T for renal cell carcinoma): Phase 1

  • Diabetes Program: with Vertex (VX-880, VX-264) – gene-edited pancreatic cells

  • Broad ex vivo and in vivo pipeline including oncology and regenerative medicine


4. Financials & Valuation

MetricBEAMCRSP
Market Cap~$1.4B~$5.8B
Cash Reserves~$1B~$1.6B
RevenueMinimalYes (Vertex partnership + CASGEVY)
ProfitabilityNoNo (revenue generating but not profitable)

Commentary: BEAM trades near its cash value after a 75% decline from its 2021 peak. CRSP has begun generating revenue but is still early in its commercialization phase. BEAM represents high-upside speculative value, while CRSP offers more de-risked exposure.


5. Value to the Medical Community

  • BEAM (Base Editing) offers future potential for highly specific gene correction therapies with fewer side effects—ideal for treating genetic diseases caused by single-point mutations.

  • CRSP (Cas9) brings scalable solutions to market today, with transformative therapies for blood disorders and cancer.

  • Complementary Impact: CRSP addresses urgent medical needs now; BEAM could deliver more refined, next-generation solutions in the near future.


6. Investment Rationale: Blended Strategy

Portfolio Blend Recommendation:

  • 60% CRSP: Stronger near-term catalysts and commercial success

  • 40% BEAM: High-risk/high-reward innovation with upside from BEAM-302

Why this split?

  • CRSP's 60% allocation balances the portfolio with a company already generating revenue from approved therapies, strong partnerships, and a broad, maturing pipeline. This reduces overall volatility and provides more immediate return potential.

  • BEAM's 40% allocation captures the promise of base editing, which could be transformative but remains in early human trials. With the stock trading near cash value and a strong balance sheet, it presents an attractive speculative opportunity with asymmetric upside.

Alternative Allocations:

  • Aggressive investors may tilt 60% BEAM / 40% CRSP for higher potential returns.

  • Defensive investors could consider 75% CRSP / 25% BEAM and optionally include Vertex Pharmaceuticals (VRTX) for indirect exposure.

Catalyst Watch:

  • BEAM-302 clinical updates (late 2025)

  • CASGEVY revenue performance

  • VX-880 (CRSP/Vertex) trial results for diabetes


7. Final Assessment


Investing in both BEAM and CRSP offers:

  • Diversified exposure to today’s gene editing therapies and tomorrow’s precision medicines

  • A hedge between early innovation and regulatory-approved commercialization

  • Long-term upside in a sector poised to transform medicine over the next decade

Conclusion: For investors with a multi-year horizon and an interest in healthcare disruption, a BEAM + CRSP combined portfolio is a strategic play on the future of genetic medicine. The suggested allocation strategy allows for tailored risk exposure depending on the investor’s goals and conviction in each platform’s long-term success.

June 2025

How Beam Therapeutics (BEAM) in collaboration with researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia saved baby KJ



Friday, July 12, 2024

If ChatGPT was a retail investor, what companies might it be considering investing in now? Here's the answer!

 

ChatGPT pictured as a future technology agent by Dall E3

As an AI, I don't have personal opinions or the ability to invest, but I can provide an analysis based on current trends and data. Here are some sectors and companies that might be of interest to retail investors:

  1. Technology and Artificial Intelligence

    • NVIDIA (NVDA): Leading in AI and GPU technology.
    • Microsoft (MSFT): Significant investments in AI and cloud computing.
    • Alphabet (GOOGL): Heavy involvement in AI through Google and other ventures.
  2. Biotechnology and Healthcare

    • Ginkgo Bioworks (DNA): Specializes in synthetic biology, a growing field with potential for substantial impact.
    • Moderna (MRNA): Known for its mRNA technology, which has broad applications beyond COVID-19 vaccines.
    • CRISPR Therapeutics (CRSP): Leader in gene editing technology.
  3. Renewable Energy and Sustainability

    • Tesla (TSLA): Dominates the electric vehicle market and is expanding into energy solutions.
    • NextEra Energy (NEE): Major player in renewable energy, particularly wind and solar.
    • Enphase Energy (ENPH): Leading provider of solar energy solutions.
  4. Quantum Computing

    • IONQ (IONQ): Pioneering in quantum computing hardware and software.
    • Rigetti Computing: Focuses on developing quantum integrated circuits.
    • D-Wave Systems: Known for its quantum annealing technology.
  5. Semiconductors

    • Advanced Micro Devices (AMD): Continues to gain market share in CPUs and GPUs.
    • Taiwan Semiconductor Manufacturing Company (TSMC): Leading manufacturer of advanced semiconductor technology.
    • Intel (INTC): Investing heavily in future technologies to regain market leadership.
  6. Electric Vehicles and Autonomous Driving

    • Lucid Group (LCID): Promising new player in the luxury EV market.
    • NIO Inc. (NIO): Leading EV manufacturer in China with global aspirations.
    • Waymo (subsidiary of Alphabet): Pioneer in autonomous driving technology.
  7. Fintech and Digital Payments

    • Square (SQ): Expanding its ecosystem of financial services and digital payments.
    • PayPal (PYPL): Strong player in digital payments and expanding into cryptocurrency.
    • Adyen (ADYEN): Provides payment solutions for global enterprises.

These suggestions are based on current market trends and the potential for growth in their respective fields. Always conduct thorough research and consider your financial situation and risk tolerance before making any investment decisions.

...................................................................................................................................................................

Several companies are considered first movers and leaders in the Quantum-as-a-Service (QaaS) sector. Here are some of the prominent ones:

1. IonQ Inc.

  • Overview: Based in College Park, Maryland, IonQ is recognized for its advanced quantum computing technology. It is known for developing the first commercially viable quantum computer using ion trap technology.
  • Collaborations: IonQ collaborates with major tech companies like Amazon and Microsoft and is involved in projects with the U.S. Defense Advanced Research Projects Agency (DARPA).
  • Growth Projections: The company is projected to have a compounded annual growth rate (CAGR) of 100% over the next few years​ (Green Bull Research)​​ (Affiliate UNguru)​​ (The Daily World)​.

2. Microsoft

  • Overview: Microsoft has been a significant player in the QaaS space, heavily investing in quantum computing and AI technologies.
  • Initiatives: The company has launched Azure Quantum, a cloud service that provides access to various quantum hardware and software solutions, making quantum computing more accessible to businesses and researchers.
  • Collaborations: Microsoft has partnered with quantum computing startups like Photonic and is actively developing its own quantum computing hardware and software​ (The Daily World)​​ (Ground News)​.

3. IBM

  • Overview: IBM is one of the pioneers in the quantum computing industry. It offers IBM Quantum Experience, a cloud-based platform that provides access to IBM's quantum processors.
  • Initiatives: IBM has developed the Qiskit framework, an open-source quantum computing software development kit, and has a robust ecosystem for quantum research and development.
  • Collaborations: IBM collaborates with academic institutions, research labs, and private sector companies to advance quantum computing technology and applications​ (Green Bull Research)​.

4. Google (Alphabet Inc.)

  • Overview: Google has been at the forefront of quantum computing research, achieving significant milestones like demonstrating quantum supremacy.
  • Initiatives: Google offers QaaS through its Google Quantum AI division, which provides access to its quantum processors and tools via cloud services.
  • Achievements: Google's quantum computer, Sycamore, solved a problem in minutes that would take classical supercomputers thousands of years, marking a major breakthrough in the field​ (Green Bull Research)​​ (Affiliate UNguru)​.

5. Rigetti Computing

  • Overview: Rigetti Computing is a notable player in the quantum computing space, focusing on developing quantum integrated circuits.
  • Initiatives: The company offers QaaS through its Rigetti Quantum Cloud Services, enabling users to run quantum algorithms and applications on its quantum processors.
  • Collaborations: Rigetti collaborates with various research institutions and tech companies to push the boundaries of quantum computing applications​ (Green Bull Research)​.

These companies are leading the charge in making quantum computing more accessible and practical for various industries through their QaaS offerings, driving innovation and potential commercial applications in the near future.

In Bio Science, there is a race for better Gene sequencing and genomics technology!

Tuesday, May 21, 2024

Investor John Templeton got his start in penny stocks. Here are some large companies that were once pennystocks!

Let’s explore how some of these tech giants 

and other companies were once penny stocks:



  1. Apple (NASDAQ: AAPL): Apple, founded in 1976, had its ups and downs. With nine stock splits taken into account, it was in penny stock territory as recently as 1995. Now, it trades above $300 a share1.
  1. Ford Motor Company (NYSE: F): Ford, a Fortune 500 company, was also once a penny stock. It has come a long way since then2.
  1. Amazon (NASDAQ: AMZN): Believe it or not, Amazon was once a penny stock too. Its remarkable growth turned it into the e-commerce giant we know today3.
  1. Google (now Alphabet): Google (now part of Alphabet) started as a penny stock when it went public in 2004. Its search engine dominance and expansion into various tech sectors transformed it into a powerhouse1.
  1. Microsoft (NASDAQ: MSFT): Microsoft, with its stock splits considered, was in penny stock territory until the mid-1990s. It has since become one of the world’s most valuable companies1.

These transformations demonstrate the potential for substantial growth

even from humble beginnings!


As an interesting side note, in 1998 when Amazon was still in it's infancy, Jeff Bezos was not a multi billionaire. 

However, he saw a company that he believed had a vision for the future.  He invested $250,000 (a large sum for him at the time) into that company. That company was Google!

Bezos turned that modest $250,000 investment into $7.9 billion 

a 3 million percent-plus return



Here are five more companies that were once penny stocks that have achieved significant success:


  1. Sirius XM Holdings Inc. (SIRI): Sirius XM, one of the world’s biggest audio and communication companies, was once a penny stock trading at only $0.60 about 10 years ago. It has since grown over 965% and expanded its reach with the addition of Pandora Radio1.
  1. Accelerate Diagnostics Inc. (AXDX): Focused on solving antibiotic resistance challenges, Accelerate Diagnostics has seen substantial growth. Its stock was once considered a very small penny stock but has risen significantly since then1.

Remember, investing in penny stocks can be risky, but these examples show that with the right catalysts and timing, substantial growth is possible! 


Are there hidden gems in today's crop of penny stocks with new technology?

We currently own shares in these Microcap companies!

: 

DNA RXRX IONQ QBTS OUST AEVA WONDR CHPT ADPT OPEN EDIT CRSP STEM PLUG